From octreotide to shorter analogues: Synthesis, radiolabeling, stability-Reference-Cited by-同舟云学术

From octreotide to shorter analogues: Synthesis, radiolabeling, stability

Published:2019-09 Issue:11 Volume:62 Page:718-728
ISSN:0362-4803
Container-title:Journal of Labelled Compounds and Radiopharmaceuticals
language:en
Short-container-title:J Label Compd Radiopharm

Author:

Yakusheva Anzhelika¹^ORCID,Titchenko Nikolay²,Egorova Bayirta¹^ORCID,Matazova Ekaterina¹,Podkhalyuzina Natalya²,Osipov Vasily³,Khachatryan Derenik⁴,Avdeev Dmitry⁵,Posypanova Galina⁶,Kalmykov Stepan¹

Affiliation:

1. Lomonosov Moscow State University; Department of Chemistry, Moscow Russia

2. D. Mendeleev University Of Chemical Technology of Russia; Organic Chemistry division, Moscow Russia

3. N.N. Blokhin National Medical Research Centre of Oncology of the Health Ministry of Russia; Institute of experimental diagnosis and therapy of tumors, Chemical synthesis laboratory, Moscow Russia

4. NRC “Kurchatov Institute”-IREA; The natural compound laboratory, Moscow Russia

5. National Medical Research Center for Cardiology; Moscow Russia

6. NRC “Kurchatov Institute”; Kurchatov Complex of NBICS Nature-Like Technologies, Cell Biology and Molecular Medicine Lab, Moscow Russia

Funder

Российский Фонд Фундаментальных Исследований

Publisher

Wiley

Subject

Organic Chemistry,Spectroscopy,Drug Discovery,Radiology, Nuclear Medicine and imaging,Biochemistry,Analytical Chemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jlcr.3799/fullpdf

Reference34 articles.

1. Radiolabeled Somatostatin Analogues in the Treatment of Non-GEP-NET Tumors

2. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study;Bodei;Eur J Nucl Med Mol Imaging,2011

3. Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumoursImpatto della fusione di immagini SPECT/TC con 111In-DTPA-octreotide nel management dei tumori neuroendocrini;Castaldi;Radiol Med,2008

4. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study;Waldherr;Ann Oncol,2001

5. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study;Pfeifer;J Nucl Med,2012

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preparation of 155Tb-labeled short somatostatin analog;Russian Chemical Bulletin;2023-09

2. [161Tb]Tb-Thz-Phe-D-Trp-Lys-Thr-DOTA: A potential radiopharmaceutical for the treatment of neuroendocrine tumors;Mendeleev Communications;2023-07

3. Influence of octreotide on apoptosis and metabolome expression in lipopolysaccharide-induced A549 cells;Heterocyclic Communications;2023-01-01

4. Synthesis of precursors for obtaining targeted radiopharmaceuticals based on short peptides, analogs of the hormone somatostatin;Russian Chemical Bulletin;2022-12

5. The Crystal Structure Elucidation of a Tetrapeptide Analog of Somatostatin DOTA-Phe-D-Trp-Lys-Thr-OMe;Crystals;2021-12-22